Original articleMultiple sclerosis therapy: historical and future perspectivesMontalbán, Xavier Author Information Vall d'Hebron University Hospital, Barcelona, Spain Correspondence to Xavier Montalbán, Vall d'Hebron University Hospital, Barcelona, Spain Tel: +34 93 274 6202; fax: +34 93 274 6084; e-mail: [email protected] Current Opinion in Neurology: March 2009 - Volume 22 - Issue - p S1-S3 doi: 10.1097/01.wco.0000347400.31774.59 Buy Metrics Abstract The introduction of disease-modifying drugs (DMDs) heralded major progress in the treatment of patients with relapsing forms of multiple sclerosis (MS). Further advances are likely in the future, with several new oral therapies already in development. Advances in magnetic resonance imaging (MRI) technology and pharmacogenomics research may eventually lead to the development and application of personalized therapeutic strategies, which could potentially incorporate both current and novel DMDs. The available evidence on the efficacy and safety of existing drugs, combined with the wide range of ongoing trials of novel agents, support a very promising future for MS therapy. © 2009 Lippincott Williams & Wilkins, Inc.
